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Objective: The necessity of bone scans in newly diagnosed prostate cancer patients is still a matter of
debate. We attempt to evaluate the validity of currently published guidelines by analyzing bone scan
results in newly diagnosed prostate cancer (PCa) patients to determine the optimal staging strategies.
Materials and methods: Between January 2011 and July 2014, there were 362 consecutive newly diag-
nosed PCa patients at Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Bone scans were
performed for all patients at initial staging. Patients positive for bone metastasis were characterized at
diagnosis in terms of age, prostate-speciﬁc antigen (PSA) level, Gleason score (GS), and clinical stage. We
analyzed the sensitivity and speciﬁcity of the American Urological Association (AUA) best practice policy,
European Association of Urology guidelines, National Comprehensive Cancer Network guidelines, and
the classiﬁcation and regression tree by Briganti et al for diagnostic performance in predicting bone
metastasis.
Results: A total 73 of 362 (20.2%) patients were diagnosed with bone metastasis. Patients positive for
metastasis on bone scans had signiﬁcantly higher PSA levels (median: 196.5 ng/mL, interquartile range:
904.3 vs. median: 18.5 ng/mL, interquartile range: 35.7; p < 0.001) and higher GSs (8.5 ± 1.0 vs. 7.0 ± 1.6;
p < 0.001) than those with negative bone scan results. Pairwise comparisons in receiver operating curve
analysis demonstrated that the AUA guidelines had a larger area under the curve than the other
guidelines.
Conclusion: The current AUA guidelines for the recommendation of staging bone scans had better pre-
diction and application rates than other guidelines in our patient cohort.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. All rights reserved.1. Introduction
The prevalence of prostate cancer (PCa) has been increasing in
recent years, especially in Asia. Digital rectal examination (DRE)
and measurement of prostate-speciﬁc antigen (PSA) levels are the
most common tools for early screening of PCa. A biopsy is recom-
mended if DRE and/or PSA test results indicate any abnormalities.
Upon deﬁnitive tissue diagnosis, further treatment strategies are
based on the results of cancer staging. Based on the clinical stage,
Gleason score (GS), and PSA level, PCa patients can be stratiﬁed into
low-, intermediate-, and high-risk groups. The initial stagingaohsiung Medical University
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rological Science (2015), httpworkup is dependent on the risk group. For high-risk PCa patients,
further treatment plans are determined based on the presence of
distant metastasis. As the most frequent site of distant metastasis
from PCa is bone tissue,1 further bone scan staging is recommended
by current published guidelines. Due to some well-studied limita-
tions of bone scans, which are potentially unnecessary for low-risk
patients but underused for high-risk patients,2 the necessity of
routine bone scan screening is still a matter of debate. The Amer-
ican Urological Association (AUA) recently recommended the
avoidance of bone scans in low-risk patients as their ﬁrst priority in
the national Choosing Wisely program.3 In addition, the current
published guidelines are based on aWestern database and previous
studies have shown that almost half of the newly diagnosed PCa
patients in the USA belong to the low-risk group.4 Therefore, there
has been an increase in active surveillance. However, the propor-
tion of intermediate- and high-risk patients is still high in Asianan LLC. All rights reserved.
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Figure 1. Receiver operating characteristic (ROC) curve analysis for different guide-
lines. AUA ¼ American Urological Association; CART ¼ classiﬁcation and regression
tree; EAU ¼ European Association of Urology; NCCN ¼ National Comprehensive Cancer
Network.
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patients with caution.5,6 Here, we evaluated the validity of
currently published guidelines by analyzing bone scan results in
newly diagnosed PCa patients to determine the optimal staging
strategies.
2. Materials and methods
2.1. Patients
Between January 2011 and July 2014, we enrolled 362
consecutive newly diagnosed PCa patients at Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan. The present study was
supervised by the Institutional Review Board of the Kaohsiung
Medical University Hospital. Transrectal ultrasound-guided pros-
tate biopsies were performed based on abnormal DRE or PSA test
results. Patients receiving 5-alpha-reductase inhibitor treatment
were excluded. A standard 18-gauge biopsy needle was used.
There were 12 routine biopsy sites, with additional targeted bi-
opsies for any suspicious lesions. A routine bone scan was per-
formed as part of our conventional workup for newly diagnosed
PCa patients.
2.2. Bone scintigraphy
Bone scintigraphy was performed after intravenous injection of
20 mCi (740 MBq) of technetium-99m methylene diphosphonate.
Whole body imaging was performed under a large ﬁeld-of-view
gamma camera (Siemens, e.cam, Erlangen, Germany) coupled to a
high-resolution collimator. Scans were interpreted by two inde-
pendent, experienced nuclear medicine physicians. Patients with
uncertain bone scan ﬁndings underwent further computed to-
mography or magnetic resonance imaging to conﬁrm the ﬁnal
diagnosis. Patients with positive bone scan results were analyzed
for PSA level at diagnosis, clinical stage, and GS.
2.3. Guidelines for bone scan recommendation
We then evaluated the sensitivity and speciﬁcity of the AUA
best practice policy,7 European Association of Urology (EAU)
guidelines,8 National Comprehensive Cancer Network (NCCN)
guidelines,9 and the classiﬁcation and regression tree (CART) by
Briganti et al.10 According to AUA guidelines, patients with poorly
differentiated tumors or PSA level > 20 ng/mL were recommended
for bone scans.7 EAU guidelines8 recommended that patients with
GS > 7, locally advanced disease, or PSA level > 10 ng/mL undergo
staging bone scans. According to NCCN guidelines,9 staging bone
scans should be performed in patients with GS > 7, clinical stage
T3/4, cT1 with PSA level > 20 ng/mL, or cT2 with PSA level >
10 ng/mL. A bone scan should be considered for patients with a
GS > 7 or PSA level > 10 ng/mL with a palpable tumor (cT2/3),
according to the CART by Briganti et al.10 A receiver operating
characteristics (ROC) curve analysis was used to compute area
under the curve (AUC) estimates to compare the different guide-
lines (Figure 1).
All data are expressed as mean ± standard deviation (median
with interquartile range in nonGaussian distribution data).
Continuous parameters were assessed using a t test or Man-
neWhitneyeWilcoxon test. Dichotomous variables were evaluated
using a Chi-square analysis to deﬁne various patient groups ac-
cording to variables that signiﬁcantly correlated with positive bone
metastasis ﬁndings. Statistical signiﬁcance was set at p < 0.05. SPSS
version 20.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical
analyses.Please cite this article in press as: Lu Y-M, et al., The most suitable guid
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The mean patient age was 71.9 ± 8.5 years (range: 48e94 years).
The mean PSA level and biopsy GS were 241.1 ± 1082.4 ng/mL and
7.3 ± 1.6, respectively. Of 362 patients, 73 (20.2%) were diagnosed
with bonemetastasis. Patients with positive bone scan results had a
signiﬁcantly higher PSA level (median: 196.5 ng/mL, interquartile
range: 904.3 vs. median: 18.5 ng/mL, interquartile range: 35.7;
p < 0.001) and a higher GS (8.5 ± 1.0 vs. 7.0 ± 1.6; p < 0.001) than
those with negative bone scan results (Table 1). Of this subset of
patients, PSA levels were  10 ng/mL in two (2.3%) patients,
10.1e20 ng/mL in four (5.2%) patients, 20.1e50 ng/mL in 12 (14.3%)
patients, 50.1e100 ng/mL in 10 (24.4%) patients, and > 100 ng/mL in
45 (60.8%) patients (Figure 2). There were no bone metastases in
patients who had a GS < 5. Bonemetastasis was found in one (2.6%)
patient with a GS of 5, in one (1.6%) patient with a GS of 6, in 13
(16.3%) patients with a GS of 7, in 15 (23.8%) patients with a GS of 8,
in 35 (41.2%) patients with a GS of 9, and in eight (57.1%) patients
with a GS of 10 (Figure 3).
The number of patients for whom a bone scan was considered
according to each set of guidelines was as follows: 238 (65.7%)
patients by AUA guidelines, 302 (83.4%) patients by EAU guidelines,
306 (84.5%) patients by NCCN guidelines, and 289 (79.8%) patients
by CART by Briganti et al.10
The McNemar test demonstrated that there were no differ-
ences between the NCCN and EAU guidelines for bone scan rec-
ommendations. Other pairwise comparisons showed signiﬁcantly
different suggestions (AUA vs. Briganti, AUA vs. NCCN, AUA vs.
EAU, EAU vs. Briganti, NCCN vs. Briganti; all p < 0.001). The
sensitivity, speciﬁcity, and accuracy rate were as follows: 94.5%,
41.5%, and 52.2% for AUA guidelines, 98.6%, 20.4%, and 36.2% for
EAU guidelines, 98.6%, 19.0%, and 35.1% for NCCN guidelines,
98.6%, 24.9%, and 39.8% for CART by Briganti et al,10 respectively.
The AUC were 0.630 (95% conﬁdential index: 0.60~0.66) for AUA
guidelines, 0.603 for EAU guidelines (95% conﬁdential index:
0.57~0.63), 0.618 (95% conﬁdential index: 0.58~0.64), and 0.604
(95% conﬁdential index: 0.57~0.63) for CART by Briganti et al,10
respectively. Pairwise comparisons of the ROC curves showed
that the AUA guidelines had larger AUC than did the other
guidelines. One patient was not recommended by any of the
guidelines as requiring a bone scan, but the bone scan showed a
bone metastasis result.elines for performing bone scans in prostate cancer staging e One
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Table 1
Comparison of age, Gleason score, and PSA values with results of skeletal scintigraphy.
Variables Total Bone scan positive for metastasis Bone scan negative for metastasis p
N ¼ 362 n ¼ 73 n ¼ 289
Age (y)
Mean ± SD 71.9 ± 8.5 71.3 ± 8.9 72.0 ± 8.3 0.507
Median 72.0 72.0 72.0
Gleason score
Mean ± SD 7.3 ± 1.6 8.5 ± 1.1 7.0 ± 1.6 < 0.001
Median 7.0 9.0 7.0
PSA (ng/mL)
Median 25.0 196.5 18.5 < 0.001
IQR 55.5 904.3 35.7
Clinical stage, n (%) < 0.001
T1/2 161 (44.5) 11 (15.1) 150 (51.9)
T3/4 201 (55.5) 62 (84.9) 139 (48.1)
IQR ¼ Interquartile range; PSA ¼ prostate-speciﬁc antigen.
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The current guidelines for bone scan recommendations were
compared with previous reports.11e13 De Nunzio et al.11 analyzed a
database with 313 newly diagnosed PCa patients (6.4% with bone
scan-positive ﬁndings) to compare CART by Briganti et al10 and the
EAU guidelines. The overall accuracy was higher for CART (75% vs.
64%). Diagnostic performance was also higher for predicting bone
metastasis. However, another study from Korea12 showed different
results using a database with 806 patients (20% with bone metas-
tasis). The study compared the AUA guidelines, EAU guidelines, and
CART by Briganti et al10 and showed better performance for the
AUA and EAU guidelines. Another report from Japan13 with 508
patients (3.5% with bone metastasis) demonstrated that the EAU
guidelines are superior to Japanese Urological Association, NCCN,
and AUA guidelines. Merdan et al14 identiﬁed 416 patients who
underwent bone scans (of 1509 patients with newly diagnosed
PCa), including 48 (11.5%) patients with bone metastasis. They re-
ported that EAU guidelines had higher sensitivity, though sub-
stantially lower speciﬁcity was also noted. Our results showed that,
although the AUA guidelines did not reveal higher sensitivity, they
had better prediction and application rates. We conﬁrmed previous
reports showing the positive relationship between higher PSA and
GS and bone metastasis. Some studies6,10 also reported an associ-
ation between the clinical stage and an increased risk of bone
metastasis, though others have shown contradictory ﬁndings.5,14Figure 2. Percentage of bone metastasis according to the PSA level. BM ¼ bone
metastasis; PSA ¼ prostate-speciﬁc antigen.
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and bone metastasis. This might be explained by the unique clinical
proﬁles of the patients in our population. Clinical screening of PSA
was not routinely performed before, but it is wildly used in patients
with clinical symptoms until recently. Our study included 201
(55.5%) patients with clinical stage T3 or higher. The higher inci-
dence of late-stage PCa compared with that reported in other
recent studies5,6,10e14 may be explained by the more aggressive and
poorly differentiated tumors in our cohort.
Current reports from several organizations, such as AUA, EAU,
NCCN, describe criteria for recommendation of staging bone scans.
However, there is no consensus among the different referral
criteria.
With increasing health care costs, clinical physicians play an
important role in preventing patients from undergoing unnec-
essary procedures and examinations. Previous reports have sug-
gested omitting bone scans if serum PSA levels and GSs meet the
following criteria: PSA < 20 ng/mL and GS < 8;15 PSA 10 ng/mL or
GS  6;16 and PSA  20 ng/mL and GS  6.5 Another study2 has
pointed out an underutilization of bone scans in high-risk PCa
patients, for whom current guidelines suggest bone scans for
staging. These patients may harbor metastatic PCa and undergo
aggressive “curative” surgical procedures for incurable situations.
The majority of newly diagnosed PCa patients in the USA belong
to the low-risk group.4 There is almost no chance of metastatic
diseases in early-stage cancer.2 A metastatic workup is notFigure 3. Percentage of bone metastasis according to the Gleason scores. BM ¼ bone
metastasis; GS ¼ Gleason score.
elines for performing bone scans in prostate cancer staging e One
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However, we noticed a high incidence of moderate and poorly
differentiated tumors in our study cohort and the rate of metastasis
is still high in newly diagnosed PCa patients, even in low-risk pa-
tients. Due to the different characteristics of our population, the
published guidelines may not reveal the true behavior of PCa in an
Asian population. The AUA and EAU indicate high negative pre-
dictive results for asymptomatic patients with PSA < 20 ng/mL and
GS < 8. However, omission of bone scans would have resulted in a
failure to detect metastasis from PCa in four patients. Based on our
study, PCa appears to be much more aggressive in Asian pop-
ulations and published guidelines should be applied in Asian pa-
tients with caution.5,6 Our preliminary results showed the
multivariate logistic regression analysis employing the indepen-
dent predictors for positive bonemetastasis and demonstrated that
a Gleason score of  7, clinical stage  T3, and an initial PSA level of
 20 ng/mL were independent predictors of bone metastasis.
Therefore, bone scans were strongly recommended for these pa-
tients. However, bone scans can be omitted in the combinations of
PSA  10 ng/mL and Gleason score  6 at the initial diagnosis. Two
notable limitations to our study must be acknowledged: (1) it is a
retrospective analysis of a single-center series; and (2) due to the
high rate of false positive results, positive results detected by bone
scans could not be conﬁrmed by histological examination.
Based on our results, the current AUA guidelines for the
recommendation of staging bone scans had the better prediction
and application rates in our patient cohort.
Conﬂicts of interest
All authors have no conﬂicts of interest to declare.
References
1. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev
Cancer 2005;5:21e8.
2. Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scan during initial
prostate cancer workup, downstream procedures, and associated Medicare
costs. Int J Radiat Oncol Biol Phys 2014;89:243e8.Please cite this article in press as: Lu Y-M, et al., The most suitable guid
southern Taiwan medical center's results, Urological Science (2015), http3. American Urological Association: Choosing Wisely. http://www.
choosingwisely.org/. (accessed 15.02.14).
4. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in
low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:
S14e9.
5. Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, et al. Bone scan
can be spared in asymptomatic prostate cancer patients with PSA of  20 ng/
mL and Gleason score of  6 at the initial stage of diagnosis. Jpn J Clin Oncol
2011;41:1209e13.
6. Lee SH, Chung MS, Park KK, Yom CD, Lee DH, Chung BH. Is it suitable to
eliminate bone scan for prostate cancer patients with PSA  20 ng/mL? World J
Urol 2012;30:265e9.
7. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate
speciﬁc antigen best practice statement: 2009 update. J Urol 2009;182:
2232e41.
8. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.
European Association of Urology. EAU guidelines on prostate cancer. Part 1:
screening, diagnosis, and local treatment with curative intent-update 2013. Eur
Urol 2014;65:124e37.
9. National Comprehensive Cancer Network Guidelines. http://www.nccn.org/
professionals/physician_gls/pdf/prostate.pdf. (accessed 20.02.14).
10. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to
perform bone scan in patients with newly diagnosed prostate cancer: external
validation of the currently available guidelines and proposal of a novel risk
stratiﬁcation tool. Eur Urol 2010;57:551e8.
11. De Nunzio C, Leonardo C, Franco G, Esperto F, Brassetti A, Simonelli G, et al.
When to perform bone scan in patients with newly diagnosed prostate cancer:
external validation of a novel risk stratiﬁcation tool. World J Urol 2013;31:
365e9.
12. Chong A, Hwang I, Ha JM, Yu SH, Hwang EC, Yu HS, et al. Application of bone
scans for prostate cancer staging: Which guideline shows better result? Can
Urol Assoc J 2014;8:E515e9.
13. Ito Y, Kikuchi E, Maeda T, Matsushima M, Kono H, Mizuno R, et al. Bone scan in
patients with newly diagnosed prostate cancer: to perform or not? External
validation of the current available guidelines for Japanese patients. J Urol
2013;189:e901 (abstract).
14. Merdan S, Womble PR, Miller DC, Barnett C, Ye Z, Linsell SM, et al. Toward
better use of bone scans among men with early-stage prostate cancer. Urology
2014;84:793e8.
15. McArthur C, McLaughlin G, Meddings RN. Changing the referral criteria for
bone scan in newly diagnosed prostate cancer patients. Br J Radiol 2012;85:
390e4.
16. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, et al. Can
initial prostate speciﬁc antigen determinations eliminate the need for bone
scans in patients with newly diagnosed prostate carcinoma? A multicenter
retrospective study in Japan. Cancer 2002;94:964e72.elines for performing bone scans in prostate cancer staging e One
://dx.doi.org/10.1016/j.urols.2015.06.287
